Breaking News Instant updates and real-time market news.

RAD

Rite Aid

$9.90

-0.86 (-7.99%)

, XLP

Consumer Staples Sector SPDR

$56.76

-0.115 (-0.20%)

08:45
04/24/19
04/24
08:45
04/24/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Rite Aid (RAD) 8.17% +5.86, Consumer Staples Sector SPDR ETF (XLP) 0.68% +0.22, New Age Beverages (NBEV) 34.01% +0.09, Health Insurance Innovations (HIIQ) 11.38% +0.07, Financial Bear 3X (FAZ) 10.91% +0.07, Direxion Brazil Bull (BRZU) 0.93% +0.04, UBS (UBS) 0.40% +0.04, YETI Holdings (YETI) 16.23% +0.03, Papa John's (PZZA) 5.71% +0.03, and Maxwell (MXWL) 3.46% +0.02.

RAD

Rite Aid

$9.90

-0.86 (-7.99%)

XLP

Consumer Staples Sector SPDR

$56.76

-0.115 (-0.20%)

NBEV

New Age Beverages

$5.21

-0.05 (-0.95%)

HIIQ

Health Insurance Innovations

$26.16

1.34 (5.40%)

FAZ

Direxion Financial Bear 3x

$8.33

-0.195 (-2.29%)

UBS

UBS

$13.09

-0.17 (-1.28%)

YETI

Yeti

$31.64

0.72 (2.33%)

PZZA

Papa John's

$48.89

-0.365 (-0.74%)

MXWL

Maxwell

$4.38

0.01 (0.23%)

  • 25

    Apr

  • 30

    Apr

  • 02

    May

  • 06

    May

  • 14

    May

  • 17

    May

  • 20

    May

  • 28

    May

  • 03

    Jun

  • 13

    Nov

RAD Rite Aid
$9.90

-0.86 (-7.99%)

12/20/18
LOOP
12/20/18
NO CHANGE
Target $1
LOOP
Hold
Rite Aid price target lowered to $1.00 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Rite Aid to $1.00 from $1.35 and kept his Hold rating after its Q3 results. The analyst notes that while the company beat on earnings, it brought down the midpoint of its FY19 guidance, which suggests that the company is not yet an an operational inflection point. Wolf adds that while the stock trades at a discount to the drugstore group, he sees it as appropriate given the "higher debt leverage and subscale operations."
04/18/19
04/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying Morgan Stanley reported "strong" Q1 results but the shares are fairly valued. 2. Snap (SNAP) downgraded to Negative from Mixed at Vertical Group and to Neutral from Outperform at Wedbush. 3. Rite Aid (RAD) downgraded with a Sell from Neutral at Guggenheim while Walgreens Boots Alliance (WBA) was downgraded with a Neutral from Buy. 4. CF Industries (CF) downgraded to Underperform from Buy at BofA/Merrill with analyst Steve Byrne saying he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. 5. FMC Corporation (FMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
Guggenheim analyst Glen Santangelo assumed coverage of Rite Aid and downgraded the shares to Sell from the firm's Neutral rating under analyst John Heinbockel. Santangelo also lowered the price target fro Rite Aid to 35c per share, down from 45c per share. The analyst believes Rite Aid's "significant debt burden" and "high leverage will continue to limit Rite Aid's ability to work through its structural and competitive issues."
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
XLP Consumer Staples Sector SPDR
$56.76

-0.115 (-0.20%)

07/09/18
MSCO
07/09/18
NO CHANGE
MSCO
Morgan Stanley suggests getting more defensive, downgrades Tech to underweight
Morgan Stanley equity strategist Michael Wilson believes the S&P 500 could trade to 2,800-2,825 in the "very near-term," but is recommending investors use such a move higher to reduce portfolio beta and risk as he continues to expect an "aggressive rotation" toward defensive sectors at some point. Given his view of a growing probability for sustained defensive leadership, Wilson downgraded Small caps to equal weight and Technology to underweight. He also upgraded Consumer Staples and Telecom Services to equal weight from underweight.
04/15/19
UBSW
04/15/19
NO CHANGE
Target $56
UBSW
Buy
Mondelez price target raised to $56 from $51 at UBS
UBS analyst Steven Strycula raised his price target on Mondelez (MDLZ) to $56 and kept his Buy rating, saying that while the stock has already outperformed the broader Consumer Staples ETF (XLP) by 14pts year-to-date, it can "rerate" further "if global organic sales trends grow over 2.5% and FY19 operating margin targets prove conservative." The analyst notes that while growth in U.S. food is scarce, he believes that Mondelez's relative price-to-earnings valuation can expand thanks to "relative sales outperformance and a pullback in rates."
NBEV New Age Beverages
$5.21

-0.05 (-0.95%)

02/13/19
NORL
02/13/19
NO CHANGE
NORL
Outperform
Northland taking 'conservative' view of New Age Beverages' 2019 results
Northland analyst Mike Grondahl said in a note prior to the open that he believes the fact that new shelf space for larger retailers is generally not available until March/April/May of 2019 presents a challenge to Q$ revenues and earnings for New Age Beverages. Also noting that shipping of new CBD products "remains in limbo due to uncertainty from the FDA," Grondahl lowered his estimates and said he is taking a "conservative look" at 2019 for the company. However, he continues to believe New Age is well positioned for the next few years and keeps an Outperform rating on the shares.
12/03/18
ROTH
12/03/18
NO CHANGE
ROTH
New Age Beverages price target raised to $10 from $7 at Roth Capital
Roth Capital analyst David Bain maintained a Buy rating on New Age Beverages and raised his price target to $10 from $7, following the company's definitive agreement to acquire e-commerce/home delivery company Morinda Holdings for around $85M. Bain believes the acquisition "significantly improves" both base and upside valuation cases.
12/04/18
ROTH
12/04/18
NO CHANGE
Target $11
ROTH
Buy
Roth ups New Age Beverages target to $11 on Morinda acquisition
Following this morning's conference call detailing its definitive agreement to acquire Morinda, Roth Capital analyst David Bain raised his price target for New Age Beverages to $11 from $10 and reiterates a Buy rating on the shares. Morinda offers an "instantaneous, unique, world-wide" distribution platform for both New Age's current product portfolio as well as its "upcoming, potentially disruptive" offerings in cannabidiol and health sciences, Bain tells investors in a research note. The analyst adds that his new price target does not take into account announced 2019 revenue synergies from the merger or potential 2020 growth from Morninda.
01/07/19
NORL
01/07/19
NO CHANGE
Target $8
NORL
Outperform
New Age Beverages price target raised to $8 from $6 at Northland
Northland analyst Mike Grondahl raised his price target on New Age Beverages to $8 from $6, stating that he sees the important point of the Morinda Holdings acquisition being how well New Age can utilize the 160,000 DTC distribution points to sell other brands in its portfolio, especially its CBD products. He believe New Age's CBD products could ship in the near-term, stating that the Farm Bill passage should make distribution of CBD products "less of a headache." Grondahl maintains an Outperform rating on New Age Beverages shares.
HIIQ Health Insurance Innovations
$26.16

1.34 (5.40%)

03/29/19
ADAM
03/29/19
NO CHANGE
Target $62
ADAM
Buy
New court filings read positive for Health Insurance Innovations, says Canaccord
Canaccord analyst Richard Close said a court filing in the case of the FTC versus Steven Dorfman gives him increased confidence that Health Insurance Innovations is not a target of the FTC and has "minimal, if any," legal concerns over this matter. His read of the documents leads Close to believe the FTC's position is that Health Insurance Innovations is not responsible for demonstrating that products sold by Simple Health provide benefits and value and the FTC "appears not to be shifting any blame" to the company, the analyst tells investors. He keeps a Buy rating and $62 price target on Health Insurance Innovations shares.
03/22/19
FANA
03/22/19
NO CHANGE
Target $67
FANA
Strong Buy
First Analysis says Health Insurance bought back more shares than expected in Q1
First Analysis analyst Frank Sparacino raised his EPS estimates for Health Insurance Innovations after the company disclosed that it has repurchased $45.3M of stock during Q1, noting that he had been modeling $30M of buybacks in Q1 and for 2019 in total. The analyst also noted that North Carolina's Senate recently passed a bill to enable the growth of association health plans, noting that AHPs could represent a $16B total addressable market and a 70%+ increase to Health Insurance Innovations' existing total addressable market. Sparacino maintains a Strong Buy rating and $67 price target on Health Insurance Innovations shares.
03/20/19
CANT
03/20/19
NO CHANGE
Target $75
CANT
Overweight
Cantor calls Aurelius claims against Health Insurance Innovations 'unfounded'
Cantor Fitzgerald analyst Steven Halper calls the claims made by Aurelius Value against Health Insurance Innovations "unfounded." The stock in afternoon trading is down 8%, or $2.52, to $30.02. The Federal Trade Commission document used by the short seller may have been taken out of context from the ongoing legal process between the agency and Simple Health, Halper tells investors in a research note. The analyst points out Health Insurance Innovations ended its relationship with Simple in early November after the FTC issued a restraining order against the company. Halper says he was "fully aware" that Health Insurance Innovations continues to be paid for policies in force prior to the shut down of Simple Health. His understanding was that the restraining order prevented Simple Health to sell new policies. The analyst does not believe Health Insurance is in a position to cancel these policies, "but obviously consumers can," he writes. There should be no impact on revenue in 2019 from this issue as the company recognizes the estimated life time value of the plan when the plan is sold, Halper contends. The analyst finds Health Insurance Innovations "very inexpensive at current levels" and keeps an Overweight rating on the name with a $75 price target.
03/28/19
CANT
03/28/19
NO CHANGE
CANT
Overweight
Cantor sees no impact on Health Insurance Innovations from Simple Health suits
Cantor Fitzgerald analyst Steven Halper noted that new documents were posted on Wednesday concerning the pending FTC lawsuit against Simple Health and Steve Dorfman. He also noted that investors recently have been concerned about Health Insurance Innovations' past relationship with Simple and Dorfman. In his view, the documents validate his opinion that the FTC process should not impact Health Insurance Innovations "at all" and the process should put to rest the ongoing concerns. Halper, who thinks Health Insurance Innovations shares "remain compelling by any measure," keeps an Overweight rating on the stock.
FAZ Direxion Financial Bear 3x
$8.33

-0.195 (-2.29%)

UBS UBS
$13.09

-0.17 (-1.28%)

03/26/19
KBWI
03/26/19
DOWNGRADE
Target $13.5
KBWI
Market Perform
KBW sees 'tapered' buybacks for UBS, downgrades shares to Market Perform
UBS analyst Thomas Hallett downgraded UBS to Market Perform from Outperform and lowered his price target for the shares to $13.50 from $15.00. The stock in midday trading is up 5c to $11.86. After analyzing the events between UBS and Swiss regulator FINMA, the analyst reduced his estimates to reflect additional provisions for litigation. Hallett believes FINMA will require a temporary operational risk weight add-on in relation to litigation matters through a "staged approach." This will keep UBS' buybacks operational, "but tapered in nature," the analyst tells investors in a research note.
03/26/19
KBWI
03/26/19
DOWNGRADE
KBWI
Market Perform
UBS downgraded to Market Perform from Outperform at Keefe Bruyette
01/09/19
SOCG
01/09/19
DOWNGRADE
SOCG
Hold
UBS downgraded to Hold from Buy at Societe Generale
01/08/19
01/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Unilever (UN, UL) downgraded to Neutral from Buy at UBS. 2. General Dynamics (GD) downgraded to Hold from Buy at Jefferies with analyst Sheila Kahyaoglu saying despite a portfolio of "marquee assets," the company's earnings "lack momentum." 3. Principal Financial (PFG) downgraded to Neutral from Buy at Goldman Sachs with analyst Alex Scott saying he sees less upside in the shares relative to other names in his life insurance coverage universe. 4. JPMorgan (JPM), SunTrust (STI), and U.S. Bancorp (USB) were downgraded to Hold from Buy at Jefferies. 5. Maxar Technologies (MAXR) downgraded to Underperform from Neutral at Credit Suisse, to Sell at Veritas, to Market Perform from Outperform at BMO Capital, and to Sector Perform at National Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
YETI Yeti
$31.64

0.72 (2.33%)

04/11/19
04/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Hold at HSBC. 2. Apple (AAPL), Dell Technologies (DELL), and HP Inc. (HPQ) initiated with a Neutral at Credit Suisse. 3. Yeti (YETI) initiated with an Outperform at Cowen. 4. CVS Health (CVS) initiated with a Market Perform at BMO Capital. 5. Canadian Solar (CSIQ) assumed with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
COWN
04/11/19
INITIATION
Target $35
COWN
Outperform
Yeti initiated with an Outperform at Cowen
Cowen analyst John Kernan started Yeti Holdings with an Outperform rating and $35 price target. Consensus sales and earnings estimates appear conservative as the company's shift to direct-to-consumer accelerates, Kernan tells investors in a research note. Further, implied estimates around wholesale and international segments suggest additional conservatism, adds the analyst. He notes the lock-up period on insider shares ends on April 22.
03/29/19
MSCO
03/29/19
DOWNGRADE
Target $32
MSCO
Equal Weight
Morgan Stanley downgrades Yeti to Equal Weight after stock doubled year-to-date
Morgan Stanley analyst Kimberly Greenberger downgraded Yeti to Equal Weight from Overweight, stating that while she remains constructive on the company's long-term outlook, she sees much of the good news being priced in with the stock having advanced 115% year-to-date. The stock, which has risen 77% above its IPO price from last October, appears to be pricing in 5-plus years of mid-teens percentage revenue growth, which compares to her base case estimate of 11% growth, Greenberger tells investors. She raised her price target on Yeti shares to $32 from $26, driven by an increased multiple as peers have re-rated higher.
03/29/19
MSCO
03/29/19
DOWNGRADE
MSCO
Equal Weight
Yeti downgraded to Equal Weight from Overweight at Morgan Stanley
PZZA Papa John's
$48.89

-0.365 (-0.74%)

02/27/19
SPHN
02/27/19
NO CHANGE
Target $55
SPHN
Overweight
Papa John's guidance better than feared, says Stephens
Stephens analyst Will Slabaugh said Papa John's February update was "somewhat encouraging" and that the company's guidance for FY19 was "better than feared." While he expects sales and margins to remain pressured throughout 2019, Slabaugh thinks market expectations are for a choppy recovery and the quarterly report "helped to keep the hope for $2.00 in EPS power alive," he tells investors. He maintains an Overweight rating and $55 price target on Papa John's shares.
03/27/19
03/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Hold from Sell at Loop Capital with analyst Anthony Chukumba citing the recent proxy contest threat was posed by an activist hedge fund consortium amassing 5% of the company stock. 2. Papa John's (PZZA) upgraded to Hold from Sell at Stifel with analyst Chris O'Cull saying he believes the company's turnaround has entered a phase where investors believe the worst is behind it "and are willing to accord the company a hall pass to see whether the sales plan can work." 3. ON Semiconductor (ON) upgraded to Buy from Neutral at Goldman Sachs with analyst Mark Delaney saying while not immune to cyclical risks, ON has improved its exposure to secular opportunities in advanced driver assistance system image sensors, electric vehicles and the cloud. 4. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Wells Fargo with analyst Ike Boruchow saying he views the company as a "rare standout" in his space, with increased visibility, running ahead of plan and with the potential for accelerating growth in the years ahead. 5. Lumentum (LITE) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/19
STFL
03/27/19
UPGRADE
Target $45
STFL
Hold
Papa John's upgraded to Hold from Sell at Stifel
Stifel analyst Chris O'Cull upgraded Papa John's International to Hold from Sell and raised his price target for the shares to $45 from $35. The analyst believes the company's turnaround has entered a phase where investors believe the worst is behind it "and are willing to accord the company a hall pass to see whether the sales plan can work." The more optimistic sentiment stems from the view that the new board of directors and new brand spokesperson Shaquille O'Neal can reverse the declining traffic and EBITDA trends, O'Cull tells investors in a research note titled "Sell Thesis Not a Slam Dunk; Investors Optimism Outweighing Fundamentals." The analyst remains concerned that low franchisee profits will require ongoing financial support from Papa John's and declining transactions will pressure commissary profits, but he believes investor optimism will likely outweigh these fundamental issues in the near-term.
04/01/19
KERI
04/01/19
UPGRADE
KERI
Buy
Papa John's upgraded to Buy from Neutral at Kalinowski
MXWL Maxwell
$4.38

0.01 (0.23%)

08/03/18
ADAM
08/03/18
INITIATION
Target $5
ADAM
Hold
Maxwell assumed with a Hold at Canaccord
Canaccord analyst Jed Dorsheimer assumed coverage of Maxwell with a Hold rating as the company continues to transition from a technology developer to commercial supplier of ultracapacitors in the auto and other markets. Dorsheimer has a $5 price target on Maxwell shares.
02/04/19
02/04/19
DOWNGRADE
Target $4.75

Neutral
Roth Capital downgrades Maxwell to Neutral, lowers price target to $4.75
As previously reported, Roth Capital analyst Craig Irwin downgraded Maxwell (MXWL) to Neutral from Buy after the company announced a definitive buyout offer from Tesla (TSLA) at $4.75 per share, with the merger likely to close in Q2. The analyst believes Maxwell's solvent-free manufacturing could bring Tesla a path for lower battery costs, where Tesla currently has no advantage over competition. Irwin is disappointed Maxwell did not achieve higher pricing in the transaction, as automotive OEM traction for UCaps was accelerating nicely. The analyst also lowered his price target on Maxwell's shares to $4.75 from $7.
02/25/19
OPCO
02/25/19
NO CHANGE
OPCO
Oppenheimer moving to Not Rated on Maxwell
Oppenheimer analyst Noah Kaye is moving his rating on Maxwell (MXWL) to Not Rated from Outperform and rescinding his $5 price target. With the shares trading close to Tesla's (TSLA) bid, the FTC recently granting antitrust clearance and the filing of a Form S-4 by TSLA and a Schedule 14D-9 by Maxwell, the analyst's rating change assumes that the acquisition will close. While believing that Maxwell's dry battery electrode technology could be strategically valuable to a broad set of stakeholders in the EV industry, Kaye has limited visibility on the prospect of a competing bid in what looks to be a limited time window.
02/05/19
UBSW
02/05/19
NO CHANGE
Target $465
UBSW
Buy
Tesla acquisition of dry electrode technology a positive, says UBS
UBS analyst Ben Kallo views Tesla's (TSLA) acquisition of Maxwell (MXWL) as positive and said its dry electrode technology may have been the key acquisition driver. The analyst said its technology could further enable cost reductions in the lithium-ion battery manufacturing process. Kallo reiterated his Buy rating and $465 price target on Tesla shares.

TODAY'S FREE FLY STORIES

WSC

WillScot

$14.18

-0.17 (-1.18%)

21:53
06/25/19
06/25
21:53
06/25/19
21:53
Initiation
WillScot initiated at DA Davidson »

WillScot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRN

Cyren

$1.60

(0.00%)

21:32
06/25/19
06/25
21:32
06/25/19
21:32
Initiation
Cyren initiated at B. Riley FBR »

Cyren initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEC

Vectrus

$38.28

-0.12 (-0.31%)

21:32
06/25/19
06/25
21:32
06/25/19
21:32
Initiation
Vectrus initiated at B. Riley FBR »

Vectrus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSPN

OneSpan

$13.81

-0.38 (-2.68%)

21:32
06/25/19
06/25
21:32
06/25/19
21:32
Initiation
OneSpan initiated at B. Riley FBR »

OneSpan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMBM

Cambium Networks

$0.00

(0.00%)

21:29
06/25/19
06/25
21:29
06/25/19
21:29
Syndicate
Cambium Networks 5.8M share IPO price $12.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

VICI

VICI Properties

$21.80

-0.52 (-2.33%)

21:27
06/25/19
06/25
21:27
06/25/19
21:27
Syndicate
VICI Properties 100M share Secondary priced at $21.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

20:25
06/25/19
06/25
20:25
06/25/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

GIS

General Mills

$53.70

0.04 (0.07%)

, PAYX

Paychex

$84.76

-1.41 (-1.64%)

20:25
06/25/19
06/25
20:25
06/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

GIS

General Mills

$53.70

0.04 (0.07%)

PAYX

Paychex

$84.76

-1.41 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 09

    Jul

  • 10

    Jul

  • 11

    Jul

BAX

Baxter

$81.71

-0.58 (-0.70%)

19:32
06/25/19
06/25
19:32
06/25/19
19:32
Initiation
Baxter initiated at KeyBanc »

Baxter initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

FB

Facebook

$188.87

-3.69 (-1.92%)

19:21
06/25/19
06/25
19:21
06/25/19
19:21
Periodicals
Brazil court reduces fine for Facebook's refusal to share data, Reuters says »

A Brazilian federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

PCG

PG&E

$21.62

-0.02 (-0.09%)

19:01
06/25/19
06/25
19:01
06/25/19
19:01
Periodicals
PG&E bondholders seek control of utility's bankruptcy, SVBJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$20.58

-0.58 (-2.74%)

18:55
06/25/19
06/25
18:55
06/25/19
18:55
Hot Stocks
Kinder Morgan says 'very pleased' with Travis County District Court ruling »

Kinder Morgan issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$32.71

-0.47 (-1.42%)

, FDX

FedEx

$156.00

-4.88 (-3.03%)

18:37
06/25/19
06/25
18:37
06/25/19
18:37
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Micron…

MU

Micron

$32.71

-0.47 (-1.42%)

FDX

FedEx

$156.00

-4.88 (-3.03%)

AVAV

AeroVironment

$61.41

-0.52 (-0.84%)

GBT

Global Blood Therapeutics

$62.42

-0.87 (-1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 09

    Jul

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

  • 26

    Jun

18:15
06/25/19
06/25
18:15
06/25/19
18:15
General news
Breaking General news story  »

St. Louis Federal Reserve…

CMCSA

Comcast

$42.75

-0.85 (-1.95%)

, CMCSK

Comcast

$0.00

(0.00%)

18:06
06/25/19
06/25
18:06
06/25/19
18:06
Periodicals
NBC to pull 'The Office' from Netflix in 2021, CNBC says »

Comcast's (CMCSA)…

CMCSA

Comcast

$42.75

-0.85 (-1.95%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$360.29

-10.72 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 17

    Jul

  • 25

    Jul

FDX

FedEx

$156.00

-4.88 (-3.03%)

18:03
06/25/19
06/25
18:03
06/25/19
18:03
Hot Stocks
FedEx says U.S. government placing burden on carriers with regulations »

Says lawsuit over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

18:01
06/25/19
06/25
18:01
06/25/19
18:01
Hot Stocks
FedEx says Huawei packages 'only peripherally' involved in U.S. lawsuit »

Says there's been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

QD

Qudian

$8.46

-0.275 (-3.15%)

18:00
06/25/19
06/25
18:00
06/25/19
18:00
Syndicate
Breaking Syndicate news story on Qudian »

Qudian files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$156.00

-4.88 (-3.03%)

, AMZN

Amazon.com

$1,879.26

-34.17 (-1.79%)

17:57
06/25/19
06/25
17:57
06/25/19
17:57
Hot Stocks
Breaking Hot Stocks news story on FedEx, Amazon.com »

FedEx says loss of Amazon…

FDX

FedEx

$156.00

-4.88 (-3.03%)

AMZN

Amazon.com

$1,879.26

-34.17 (-1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 10

    Jul

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:56
06/25/19
06/25
17:56
06/25/19
17:56
Hot Stocks
FedEx sees buyback level significantly lower in FY20 »

Says has created new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:51
06/25/19
06/25
17:51
06/25/19
17:51
Hot Stocks
FedEx says has made no pricing changes »

Says business realignment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:46
06/25/19
06/25
17:46
06/25/19
17:46
Hot Stocks
FedEx says international commercial team still poised for growth »

Says TNT Express…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:43
06/25/19
06/25
17:43
06/25/19
17:43
Hot Stocks
FedEx says global trade picture 'less than ideal' »

Says "all-in"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:38
06/25/19
06/25
17:38
06/25/19
17:38
Hot Stocks
FedEx calls FY20 a 'transition year' »

Says FY20 a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:37
06/25/19
06/25
17:37
06/25/19
17:37
Hot Stocks
FedEx says intends to substantially grow e-commerce business »

Sees FedEx Freight will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.